In partnership with Dr Bart Dolmatch at Palo Alto Medical Foundation, the company developed the device in 2010.

Autologous arteriovenous access is the key to long-term success with hemodialysis ... an arteriovenous graft of synthetic material or a transposed brachial basilic vein fistula.

Merit Medical Systems, Inc. MMSI recently announced the FDA's premarket approval for the WRAPSODY Cell-Impermeable ...

Unique cell-impermeable 1 design extends life-saving treatment for dialysis patients; Merit to host a WRAPSODY informational call on January 28, 2025; SOUTH JORDAN, Utah, Dec. 20, ...

Results from the WAVE pivotal trial demonstrated that AV fistula and AV graft patients treated with the Wrapsody device for dialysis outflow lesions achieved a target lesion primary patency of 89.8% ...

In our practice, a commitment to autologous access began even before the publication of the DOQI guidelines. Early in our experience, prosthetic grafts were generally the third line of ...

(RTTNews) - Merit Medical Systems, Inc. (MMSI), Friday announced that its Wrapsody Cell-Impermeable Endoprosthesis has secured premarket approval from the Food and Drug Administration, enabling its ...

Many patients undergoing dialysis rely on a vascular access site created in the arm called an arteriovenous (AV) fistula (surgically joining an artery and vein) or an AV graft (a soft tube placed ...